ArticleArchives of osteoporosis2026
Bone mineral density testing rates and fracture risk across cancers with different mortality risks: a nationwide matched cohort study.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our study, patients with cancer underwent bone mineral density testing more frequently than matched non-cancer patients. High-mortality cancers showed the highest relative rates of both BMD testing and osteoporotic fracture, whereas thyroid cancer showed comparatively low fracture risk despite higher testing rates.
backgroundWe aimed to compare the rates of bone mineral density (BMD) testing and osteoporotic fractures among patients with incident cancer and matched non-cancer patients according to cancer mortality risk.
methodsWe conducted a nationwide matched cohort study of individuals aged ≥ 50 years between 2005 and 2019. Patients with incident cancer were risk-set matched 1:2 to non-cancer patients using time-dependent propensity scores. Cancer types were categorized by mortality risk (thyroid, intermediate-, and high-mortality). Outcomes included receipt of BMD testing and incidence of osteoporotic fractures within 5 years. Cox proportional hazards models with robust variance estimators were used, with stratified analyses according to prior osteoporosis medication use.
resultsThe final cohort comprised 28,537 patients with cancer and 57,074 matched non-cancer patients. Overall, patients with cancer were more likely to undergo BMD testing than non-cancer patients; however, the magnitude varied by cancer mortality risk. Among patients without prior osteoporosis treatment, BMD testing was most frequent in high-mortality cancers (adjusted hazard ratio [aHR] 2.17; 95% CI 2.12-2.23), followed by thyroid (aHR 1.59; 95% CI 1.48-1.71) and intermediate-mortality cancers (aHR 1.49; 95% CI 1.45-1.54). In contrast, osteoporotic fracture risk increased stepwise with worsening cancer prognosis, with the highest risk observed in high-mortality cancers (aHR 2.80; 95% CI 2.72-2.89), while thyroid cancer was not associated with increased fracture risk.
conclusionsBoth BMD testing and fracture risk varied across cancer mortality groups, with high-mortality cancers showing the highest relative fracture risk. These findings demonstrate differing rates of BMD testing and osteoporotic fracture across cancer populations with differing prognoses.
Indexed as
Identifiers
42343050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.